白三烯受体拮抗剂对儿童急性喘息性支气管炎的疗效研究

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (35 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical efficacy of Montelukast Sodium of leukotriene receptor antagonist on children with acute asthmatic bronchitis. Methods A total of 80 children with acute asthmatic bronchitis admitted to our hospital from January 2018 to June 2019 were selected and divided into the observation group (40 cases) and the control group (40 cases) according to the different treatment methods.The control group was treated with routine treatment,the observation group was treated with Montelukast Sodium of leukotriene receptor antagonist on this basis.The clinical efficacy,the time of clinical symptom relief,the recurrence rate of wheezing,inflammatory mediators and the safety of treatment were compared between the two groups. Results The total effective rate of the observation group was 95.00%,which was higher than that of the control group (77.50%),the difference was statistically significant (P＜0.05).The recurrence rate of wheezing was 5.00% in the observation group within 6 months after treatment,which was lower than 25.00% in the control group,the difference was statistically significant (P＜0.05).The wheezing relief time,wheezing disappeared time,cough subsided time and hospitalization time in the observation group were shorter than those in the control group,the levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) of the observation group were lower than those of the control group,the differences were statistically significant (P＜0.05).There was no significant difference in the total incidence of adverse reactions between the two groups (P＞0.05).Conclusion The treatment of Montelukast Sodium of leukotriene receptor antagonists in children with acute asthmatic bronchitis can effectively improve the clinical efficacy,promote the relief of clinical symptoms,improve the inflammatory response,reduce the recurrence of asthma,and have a high safety.

Key words： Acute asthmatic bronchitis Leukotriene receptor antagonists Inflammatory response Montelukast sodium Safety

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WU Zhuo-jian
	ZHONG Mei-gong
	TAN Wen-qiang
	LI Jun-wen
	XU Jie
	LIANG Fa-liang
	FENG Yue-hua

Cite this article:

WU Zhuo-jian,ZHONG Mei-gong,TAN Wen-qiang, et al. Clinical efficacy study of Montelukast Sodium of leukotriene receptor antagonist on acute asthmatic bronchitis in children[J]. 中国当代医药, 2020, 27(21): 103-105.

URL:

https://dangdaiyiyao.com/EN/ OR https://dangdaiyiyao.com/EN/Y2020/V27/I21/103

[1]	金瑄，王丽.干扰素α1b 联合孟鲁司特钠治疗小儿喘息性支气管炎疗效观察[J].海南医学，2017，28（4）：654-655.
[2]	王斌，吴静华，李永权.孟鲁司特钠治疗小儿喘息性支气管炎的疗效及对气道高反应性的预防效果分析[J].医学综述，2016，22（8）：1600-1602.
[3]	廖先辉，林世飞.孟鲁司特钠联合阿奇霉素治疗小儿喘息性支气管炎的临床疗效[J].儿科药学杂志，2016，22（7）：24-27.
[4]	刘宗文.孟鲁司特钠防治喘息性支气管炎的临床观察[J].北京医学，2016，38（7）：647，653.
[5]	陆再英，钟南山.内科学[M].7 版.北京：人民卫生出版社，2011：123-125.
[6]	胡亚美，江载芳.诸福棠实用儿科学[M].7 版.北京：人民卫生出版社，2002：1199-1200.
[7]	马静.复方鲜竹沥液联合特布他林治疗儿童喘息性支气管炎的临床研究[J].现代药物与临床，2019，34（9）：2636-2639.
[8]	钟绍杰，黎海龙，孙君璐.喜炎平注射液治疗小儿喘息性支气管炎疗效观察[J].海南医学，2017，28（9）：1424-1425.
[9]	左立旻，贺月秋，陈凌梅，等.孟鲁司特钠与氢化可的松琥珀酸钠联合在小儿喘息性支气管炎中的应用分析[J].中国医院药学杂志，2016，36（24）：2194-2198.
[10]	孙琦玮，曲政海，管恩本.吸入糖皮质激素治疗婴幼儿轻度喘息性支气管炎效果[J].齐鲁医学杂志，2016，31（4）：458-459.
[11]	姜红，侯丽洁.孟鲁司特对毛细支气管炎患儿IL-17 和IL-23 表达的影响以及临床疗效分析[J].临床肺科杂志，2016，21（6）：1021-1023.
[12]	唐露.双黄连注射液对喘息性支气管炎患儿炎性介质水平的影响[J].陕西中医，2016，37（11）：1512-1513.
[13]	杨积宝.金贝痰咳清颗粒联合孟鲁司特钠治疗儿童喘息性支气管炎的临床研究[J].现代药物与临床，2019，34（3）：750-754.
[14]	张媛，张铁栓.孟鲁司特联合布地奈德治疗嗜酸粒细胞性支气管炎的疗效及预防复发作用[J].实用医学杂志，2016，32（1）：121-123.
[15]	朱彩华，孙文武，张淼.孟鲁司特钠联合氢化可的松琥珀酸钠对PAB 患儿炎性细胞因子及其转录因子表达的影响[J].实用药物与临床，2019，22（6）：629-633.